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Abstract
Background: Senescence marker protein-30 (SMP30), whose expression declines during aging in
rat liver, has been proposed as an important aging marker. Besides apoptosis, SMP30 also protects
cells against various other injuries by enhancement of membrane calcium-pump activity. The
mechanism of this differential gene expression mechanism is not known. DNA-protein interactions,
mutation analysis and luciferase reporter assay studies have been performed to elucidate the
mechanism of transcriptional regulation of SMP30 gene.
Results: We have characterized up to -2750 bp of the promoter by DNA-protein interactions
studies. Twenty eight transcription factor binding sites have been identified by DNase I footprinting
and electrophoretic mobility shift assay (EMSA). Transient transfection of 5' and 3' -deleted
promoter-reporter constructs and luciferase assay illustrated the region between -128/+157 bp is
sufficient to drive promoter activity. We have mapped an essential regulatory region between -513
to -352 bp which causes a drastic decline of reporter activity. This region contains CdxA, GATA2
and SRY transcription factor binding sites. Individual mutation of these three sites showed increase
in reporter activity. Mutation in SRY site (-403/-368) showed maximum increase in reporter activity
among these three sites. Therefore, we suggest that SRY like protein may be acting as a strong
repressor of SMP30 gene along with CdxA and GATA-2. We also report that mutation of both Sp1
(172/-148 bp) and a C/EBPβ (-190/-177 bp) transcription binding site located adjacent to each other
on SMP30 gene promoter, causes a significant enhancement in reporter activity than individual
mutation, thus may be causing the repression of SMP30 promoter activity.
Conclusion: These studies provide novel insights into the mechanism that regulate SMP30 gene
expression.
Background
Senescence marker protein-30 (SMP30), a 34 kDa protein,
is preferentially expressed in hepatocytes and renal tubu-
lar epithelia. SMP30 is unique in that, its expression is
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maintained at a high level throughout the tissue matura-
tion process, then decreases in an androgen-independent
manner during senescent stages in both sexes [1,2]. Anal-
ysis of murine genomic clone revealed that SMP30 is
organized into seven exons and six introns spanning
approximately 17.5 kb. The full length cDNA fragment
(1.6 kb) contains an open reading frame of 897 bp encod-
ing 299 amino acids. Cloned SMP30 promoter is approx-
imately 3 kb in length and up to -1.5 kb of upstream
promoter region has been sequenced [2]. We have further
sequenced upstream region -3001 to -1502 bp, and the
sequence is available from the NCBI database under the
accession number EU251064. SMP30 knockout mice
though are viable and fertile have reduced body weight
and life span. SMP30 deficiency in mice causes an accu-
mulation of neural lipids and phospholipids in liver and
shortens the life span [3]. SMP30 plays an important role
in maintaining calcium homeostasis as it blunts down cell
death caused by intracellular accumulation of calcium by
enhancing plasma membranes calcium pumping activity
[1]. It also plays a profound role in rescuing cells from cel-
lular injuries such as apoptosis and hypoxia [4]. Besides,
SMP30 functions as gluconolactonase in L-ascorbic acid
biosynthesis, and its knockout mice are prone to scurvy
[5]. Recently, we have also reported the alteration of
SMP30 expression in hyperthyroidism [6]. Considering
the immense importance of SMP30 in aging and in gen-
eral physiology of an organism, it is highly essential to
understand the mechanism of SMP30 gene expression.
Regulation of gene expression at transcriptional level is
mediated by the interaction of trans-acting factors with
cis-acting DNA sequences on the promoter region of the
genes. Thus, the cross-talk between trans-acting regulatory
factors and cis-acting regulatory elements may be impor-
tant for regulation of SMP30 gene expression. The identi-
fication of cis-regulatory elements are therefore central
and detailed analyses of cis-regulatory mechanisms con-
trolling critical transcription factor will be required in
order to understand the transcriptional regulation of
SMP30 gene. Previously, we reported DNase I footprint-
ing on SMP30 promoter up to -800 bp upstream of the
transcription start site and identified eight nuclear factor
DNA binding sites in this region excluding -513 to -352
bp [7]. The aim of the present study is to characterize and
decipher the mechanism of SMP30 gene expression and
regulation. In elucidating the mechanism that endow
potent and regulated expression of SMP30, detailed char-
acterization of the promoter is highly desirable. To char-
acterize SMP30 promoter we carried out DNA-protein
interaction study by DNase I footprinting studies from -
800 bp to -2750 bp and electrophoretic mobility shift
assay. In this region about twenty eight putative transcrip-
tion factor binding sites have been identified of which ten
transcription factor binding sites were confirmed by com-
petitive EMSA. Further, to access the transcriptional mech-
anism of SMP30 gene expression and regulation, we have
carried out for the first time 5' and 3' serial deletion of
SMP30 promoter and subsequently cloned into luciferase
reporter vector. Transient transfection and luciferase assay
illustrated the region of SMP30 promoter between -128/
+157 bp (Luc-6), having significant promoter activity.
Progressive deletion study confirmed the presence of a
repressor element between -513 bp to -352 bp. DNase I
footprinting assay was carried out to chalk out the repres-
sor elements, which revealed the presence of three DNase
I protected sites. Analysis of these sequences with
TFSEARCH showed the binding of CdxA, GATA2 and SRY
transcription factors. Transient transfection of individual
site-directed mutated constructs into RAG cells and luci-
ferase assay showed an increase in reporter activity for all
the three mutated constructs.
Since mutation of SRY region (-403/-368) showed maxi-
mum reporter activity, we suggest SRY along with CdxA
and GATA-2 may be acting as a major negative regulator
of this gene. Binding of SRY, GATA-2 and CdxA to their
respective sites were confirmed by competitive EMSA.
Another interesting feature of SMP30 gene promoter is
location of Sp1 and C/EBPβ transcription factor binding
sites adjacent to each other. Here, we also report that
though the presence of these two transcription factor
binding sites to minimal promoter region (Luc-5) did not
show any significant change in reporter activity as com-
pared to Luc-6, but mutation of both the transcription fac-
tor binding site enhanced the reporter activity
significantly by 23%. This suggests either direct or indirect
interaction between Sp1 and C/EBPβ occurs at transcrip-
tional level in presence of other regulatory factor in
SMP30 promoter which causes repression in SMP30 gene
promoter activity.
Results
Identification of DNase I protected sites on SMP30 
promoter
We have previously identified eight transcription factor
binding sites within 0.8 kb mouse SMP30 promoter frag-
ment by DNase I footprinting and EMSA [7]. In this study
we further investigated the transcription factor binding
sites by DNase I footprinting assay on SMP30 promoter
region between -2750/-777 bp using rat liver nuclear
extract. The Primers used for footprinting study of the
above mentioned regions are shown in table 1. Within
this region, twenty eight DNase I protected sites were
identified (Table 2 and 3) and a representative of three
DNase I footprinting sites of the regions -1208/-777 bp, -
1491/-1205 bp and -2028/-1626 bp are shown (Figure 1,
2 and 3).BMC Molecular Biology 2008, 9:43 http://www.biomedcentral.com/1471-2199/9/43
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Confirmation of identified transcription factor binding site 
through electrophoretic mobility shift assay (EMSA)
All the DNase I protected sequences were analyzed in tran-
scription factor data base (TFSEARCH, Japan) which
revealed binding sites sequence homology to multiple
transcription factors. To demonstrate the specificity of
transcription factors binding sites to the DNase I pro-
tected regions, we carried out EMSA and/or supershift
assay. We synthesized oligonucleotides (both strands)
corresponding to the protected sites (Table 2) and pre-
pared radiolabeled duplexes for EMSA studies. Five DNase
I protected sites were identified in the region -1208/-777
bp of which FP 4 and FP 5 have been confirmed by EMSA
(Figure 4 and 5). To FP 4 site binding of C/EBPβ was con-
firmed by competition with cold C/EBP oligonucleotide
and also by C/EBPβ antibody shift experiments. Binding
of GATA-1 to FP 5 is confirmed by competition experi-
ments. Four DNase I protected sites were detected in the
region -1491/-1205 bp. Though TFSEARCH revealed the
binding GATA-3, GATA-1, GATA-2 and AML-1a in order
of decreasing binding affinity, only AML-1a competed
with FP 6 site (Figure 6). Similarly TFSEARCH revealed the
binding of Lyf-1 and GATA-1 to FP8, only cold GATA-1
oligonucleotide competed with FP 8 but not Lyf-1 thus
confirming the binding of GATA-1 to FP8 (Figure 7).
Three DNase I protected sites were detected in -2028/-
1626 bp region. Binding of no transcription factor up to
80% was observed in TFSEARCH to FP 10, thus it may be
a novel transcription factor binding site (Figure 8). Bind-
ing of SRY to FP 11 is confirmed by competition studies
(Figure 9). Table 3 shows all the DNase I protected sites
confirmed by EMSA (data not shown).
Elucidation of mechanism of SMP30 gene expression and 
regulation
To elucidate the mechanism of SMP30 gene expression,
both 5' and 3' deletion constructs were sub-cloned into
pGL3 luciferase plasmid and transiently transfected into
RAG cells. The 5' -serially deleted constructs are -920/
+157(Luc-1), -710/+157(Luc-2), -513/+157(Luc-3), -352/
+157(Luc-4), -240/+157(Luc-5) and -128/+157(Luc-6).
The 3' -serially deleted constructs are +157/-128 and
+104/-128. The expression pattern of 5' -serially deleted
constructs is shown in figure 10. The 5' -deleted -128/
+157 bp construct (Luc-6) showed highest reporter activ-
ity among others. In order to delineate the basal promoter
activity further, we carried out transfection of 3' -deletion
construct into RAG cells. The construct -128/+104 bp
showed ~ 28% reduction in reporter activity (Figure 11).
Thus, the region between -128/+157 bp is essential in
Table 1: Primers used for footprinting from -777 to -2750 kb.
Serial No Region Amplified Primers: Sense (SS) and antisense (AS)
1 -2008 to -777 SS: CAGCATTCCTGGTAGAAACAGGTCC
2 -2008 to -777 AS: GTCCTACACATGGGTGGGCAAATG
3 -1276 to -1039 SS: GCTTCCCAGAGTTCGGCCATTGTTG
4 -1276 to -1039 AS: GTCTTGCAAGCGATGTGTGTGG
5 -1491 to -1205 SS: CCCTTCCCAAGGTTCTCTGC
6 -1491 to -1205 AS:GGTTTTCCCATTGTGACGACGTCGG
7 -1695 to -1391 SS: CACTTGCTTTAACTCCTGCAGC
8 -1695 to -1391 AS: GCTTCTTCATCTTACCCACC
9 -2028 to -1626 SS: GACACACCAGGTGAGCACTGTAC
10 -2028 to -1626 AS: GGTAACTGGAAGTACCCAGC
11 -2190 to -1865 SS: CAAGGCCAGCATGGACTGC
12 -2190 to -1865 AS: GAAGACCTTGGTGGCAGCAG
13 -2448 to -2112 SS: GGTATGCATGCATGCAGTGC
14 -2448 to -2112 AS: GAGCCAATCACCTCCAGGTG
15 -2750 to -2283 SS: GAACGGCAAAGTTAGTATGAGGCC
16 -2750 to -2283 AS: GAGACAGTCCTCAAGTAGCCTGC
Table 2: DNase 1 protected sites.
Footprint DNase 1 protected region Transcription factor
FP 4 TGTGGGTTAAGCTATTGCAAAACTCCAACATCTGATCTTGGGGCTT C/EBP β
FP 5 ACCCCTCCACACACATCGCTTGCAAGACAAACTGTGGGTT GATA1
FP 6 CACCCCAATCCGGCTGAGACTGCTCTGTGAGTAGC AML-1A
FP 8 CTTGGTGGGTAAGATGAAGAAGCTAGATTTGGGCGAAGGC GATA1
FP 10 TTTGCAAGCGTTGGCCTGCTGCCACCAAGGTCTTCCC Novel
FP 11 TAAACCAAATCAAATAAAGGCATTTTTCTTCCCCTTCC SRYBMC Molecular Biology 2008, 9:43 http://www.biomedcentral.com/1471-2199/9/43
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determining the promoter activity of SMP30 gene and
sequence between +104 bp to +157 bp plays a detrimental
role during transcription.
Identification of SRY, GATA-2 and CdxA like transcription 
factor as a repressor element present between -513 and -
352 bp
The reporter assay of 5' -serially deleted constructs showed
a drastic decline (~41%) of activity of Luc-4 (-352/+157
bp) as compared to Luc-3 (-513/+157 bp). DNase I foot-
printing study of the region between -513 bp and -352 bp
revealed three distinct DNase I protected sites such as Luc
3–1, Luc 3–2 and Luc 3–3 (Figure 12). TFSEARCH
revealed the binding of CdxA to Luc 3–1, GATA-2 to Luc
3–2 and SRY to Luc 3–3. To pin point the transcription
factor which act as a repressor we prepared site directed
mutated constructs for all the three sites. Transient trans-
fection of these mutated constructs was carried out along
with wild type Luc 3 (-513/+157) (Figure 13). Mutation of
Luc3-1 leads to increase in reporter activity by 29%, Luc3-
2 by 27% and Luc 3–3 site leads to maximum increase in
reporter activity about 59%. This result revealed SRY,
CdxA and GATA-2 as the major repressor elements. To fur-
ther establish this fact, we did EMSA study using both wild
type and mutated oligonucleotide of Luc3-3 site. The wild
type Luc3-3 oligonucleotide competed with SRY specific
cold oligonucleotide consensus, but mutated 3–3 site did
not show any binding, thus establishing the binding of
SRY to this site (Figure 14). The competitive EMSA using
radiolabeled Luc3-2 oligonucleotide showed 100% com-
petition with GATA-2 (Figure 15), while EMSA using radi-
olabeled Luc 3–1 which has 85% homology revealed that
although there is competition by unlabeled Luc 3–1 oligo-
nucleotide, no significant competition is observed using
consensus CdxA site. Considering the high homology to
Cdx A consensus binding site, Luc 3–1 site may be inter-
acting with CdxA like transcription factor with slight devi-
ation in binding sequence (data not shown).
Sp1 and C/EBPβ causes repression of SMP30 promoter 
activity
SMP30 gene promoter has a Sp1 and a C/EBPβ transcrip-
tion factor binding site adjacent to each other. Sp1 site
spans between -172 to -148 bp and C/EBPβ spans
between -190 to -177 bp. Here we report that, presence of
these two sites in the minimal promoter region did not
cause any significant change in reporter activity (that is,
there is no significant change in Luc-5 as compared to Luc-
6). But site-directed mutation of both the transcription 
Table 3: DNase 1 protected sites between -777 to -2750 (data not shown)
Footprint DNase 1 protected region Transcription factor
-953 to -913 GGGCCAATTTTTAACAGCCAATGAAAATGGCAAATGCTACACA CdxA
-995 to -954 GGGGCTTATCTACGATTGATAGCATGAAGC GATA-X
-1123 to -1088 CCACCAGTTTGCAGCCAGAATTCCTGGTAGAAACAG CdxA
-1374 to -1351 CCCCTGGGAAGCTAGATTTGTTCAS R Y
-1440 to -1419 CCCTGTGAATAACCGGGACAGG HSF2
-1546 to -1520 CCCCGGGCCGGCGGCTACCTATCTGCC GATA2
-1584 to -1550 AGAAGGGTGAGCCCTCAGGATCGCTAGTCTCTGCC GATA2
-1621 to -1587 GCTGAAAAATGAAAGGACAGCGTGGGCACCCGTAG Cdxa
-1983 to -1956 GGCTATGTCATTTAGAATCGTTTATTCC Oct-1
-1994 to -1981 TAGCTATGTTTGGC SRY
-2076 to -2051 CCTATAAAATAAAGGGAAAAGAACACC TATA
-2111 to -2082 ACCTGGAGGTGATTGGCTCTGAGTTTCACC GATA1
-2134 to -2109 GGGGAGTGAGTCAGTGGTAGTGCACC Ap1
-2167 to -2141 TGAAACTGCCAAGAAATAATGTCTTAG CdxA
-2384 to -2347 TAAATAGGTTTTTAAAAAGAAAAAGAAAAAATGGGGCA SRY
-2414 to -2381 AAGCAAAGCCCTCACACACATTAAAATGAGTAAA CdxA
-2491 to -2449 GAGATGACAATTACATCAAATAATAAAAGTTATATTTACATCA CdxA
-2604 to -2562 TGGTGAGCTTATTTAATCTCAGAGACTGAAAACATTCTAGGCC HNF-3b
-2675 to -2646 GCTTGGCGAGGAGTTTTAACCCAGAACAGC SRY
-2691 to -2654 AGAAGCCAGATTGAATCAGTTGCTTGGCGAGGAGTTTTAACCC AP1
-2704 to -2691 CCAAGAGAAGAAGCC Novel
-2721 to -2703 GAGCAATTCAGGAGAGGCC Nkx-2.5
Table 4: Primers used for 5' and 3' deletion.
Luc-1 (SS) ACAGGTACCCAAATGCTACAGCGCTGG
Luc-2 (SS) ACAGGTACCAATGTCTACTGGGGTAG
Luc-3 (SS) ACAGGTACCCATGCAAGGAAGCAAG
Luc-4 (SS) ACAGGTACCCCTCATACCTGCCATTATC
Luc-5 (SS) ACAGGTACCTACCAAGCCTCTGGCTG
Luc-6 (SS) ACAGGTACCGAATGAGGGAGAGGTG
Luc-SMP-XhoI (AS) ACACTCGAGGCAAGACAGGAGGTGATTG
Luc-Exon-SMP-Xho1 ACACTCGAGCGTCTTCAGTCAACTTACCBMC Molecular Biology 2008, 9:43 http://www.biomedcentral.com/1471-2199/9/43
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DNase I footprinting analysis of SMP30 promoter between - 1208 bp to -777 bp region: Lane 1–2, represent sequencing  ladder T and C; Lane 3–4, represent DNA treated with  DNase I in absence of RLNE; Lane 5–6, represent DNA  treated with DNase I in presence of 50 μg RLNE Figure 1
DNase I footprinting analysis of SMP30 promoter 
between -1208 bp to -777 bp region: Lane 1–2, repre-
sent sequencing ladder T and C; Lane 3–4, represent 
DNA treated with DNase I in absence of RLNE; Lane 
5–6, represent DNA treated with DNase I in pres-
ence of 50 μg RLNE. The DNase I protected sites are 
marked on right site.
DNase I footprinting analysis of SMP30 promoter between - 1491 bp to -1205 bp respectively: Lane 1–2 represent DNA  treated with DNase I in absence of RLNE Figure 2
DNase I footprinting analysis of SMP30 promoter 
between -1491 bp to -1205 bp respectively: Lane 1–2 
represent DNA treated with DNase I in absence of 
RLNE.Lane 3–4, represent DNA treated with DNase I in 
presence of 50 μg RLNE and Lane 5–6, represent sequencing 
ladder T and C.BMC Molecular Biology 2008, 9:43 http://www.biomedcentral.com/1471-2199/9/43
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factor binding site caused a significant increase in reporter
activity (~23%) (Figure 5A). Individual mutation of only
Sp1 and C/EBPβ did not contribute to any significant
change in reporter activity. Mutation of Sp1 site reduced
the reporter activity by only 16% and mutation of C/EBPβ
lead to enhancement of reporter activity by only 14% (Fig-
ure 16). Binding of Sp1 to the region between -172 to -148
bp is confirmed by competitive EMSA done in presence of
100 fold molar excess of cold Sp1 consensus (Figure 17).
EMSA was also carried out using labeled mutated Sp1 oli-
gonucleotide, which showed no DNA-protein interaction,
thus confirming the inability of Sp1 to bind to the
mutated site. Binding of C/EBPβ to the region -190/-177
bp is confirmed by EMSA and antibody shift experiments
using C/EBPβ antibody (Figure 5C). EMSA study carried
out with labeled mutated C/EBP oligonucleotide also
yielded a DNA-protein complex. But this complex is not
due to binding of C/EBPβ as confirmed by competition
with C/EBPβ consensus and antibody shift experiments
(Figure 18).
Electrophoretic mobility shift assay to confirm the binding of  C/EBP transcription factor to DNase I protected site FP 4:  Lane 1, labeled FP 4 oligonucleotide duplex with 6 μg RLNE;  Lane 2 C/EBPβ antibody; Lane 3–5, describe the competition  with 100 fold molar excess of unlabeled homologous self, C/ EBP consensus, and nonspecific Oct 1 oligonucleotide duplex  respectively Figure 4
Electrophoretic mobility shift assay to confirm the 
binding of C/EBP transcription factor to DNase I pro-
tected site FP 4: Lane 1, labeled FP 4 oligonucleotide 
duplex with 6 μg RLNE; Lane 2 C/EBPβ antibody; 
Lane 3–5, describe the competition with 100 fold 
molar excess of unlabeled homologous self, C/EBP 
consensus, and nonspecific Oct 1 oligonucleotide 
duplex respectively. Antibody shift is seen with C/EBPβ 
antibody.
DNase I footprinting analysis of SMP30 promoter between - 2028 to -1626 bp respectively: Lane 1–2 represent DNA  treated with DNase I in absence of RLNE Figure 3
DNase I footprinting analysis of SMP30 promoter 
between -2028 to -1626 bp respectively: Lane 1–2 rep-
resent DNA treated with DNase I in absence of 
RLNE.Lane 3–4, represent DNA treated with DNase I in 
presence of 50 μg RLNE Lane 5–6, represent sequencing lad-
der C and T.BMC Molecular Biology 2008, 9:43 http://www.biomedcentral.com/1471-2199/9/43
Page 7 of 15
(page number not for citation purposes)
Discussion
The multiple biological functions of SMP30 in diverse tar-
get cells require its expression to be regulated precisely. It
is suggested that the transcriptional regulation of a partic-
ular gene is a complex process which usually involves
interaction between multiple cis-acting regulatory ele-
ments and their cognate protein factors [8,9]. A growing
list of transcription factors has been shown to function as
either transcriptional activator or repressor in different
gene promoter. In this study we analyzed the transcrip-
tional regulation of SMP30 gene by DNase I footprinting,
EMSA and functional characterization by transient trans-
fection, reporter assay of 5' and 3' -serially deleted pro-
moter reporter constructs and site-directed mutagenesis.
We have earlier reported eight nuclear factor binding sites
on SMP30 gene promoter [7]. In this report twenty eight
new DNase I footprinting sites were identified using rat
liver nuclear extract. We also demonstrate that the 5' -
flanking regions of SMP30 gene possess a functional pro-
moter when transfected into RAG cells. The results of 5'
and 3' -deletion analysis illustrated the region -128/+157
bp possesses significant reporter activity. The presence of
a TATA sequence (-29 ATAAAA -25) and a CAAT box (-72
CCAAT -68) were previously reported respective to the
transcription start site [2]. Our results suggest that the
TATA and CAAT box located between -128 bp and +157
bp plays an important role in determining the promoter
activity and sufficient to drive SMP30 gene expression. 3'
– deletion from +157 bp to +104 bp resulted in ~28%
decrease in basal promoter activity, thus indicating that
this region is essential for SMP30 gene expression. An
interesting feature of SMP30 promoter is the presence of
C/EBPβ binding site adjacent to Sp1 binding site. Sp1 is a
ubiquitous DNA-binding protein with three zinc finger at
its C-terminal that activates the transcription of many cel-
lular and viral genes [10]. SMP30 promoter possess a Sp1
binding site between -172 bp to -148 bp. C/EBPβ belongs
to CCAAT-enhancer-binding protein family of transcrip-
tion factors, involved in different cellular response like in
control of cellular proliferation, growth and differentia-
tion, metabolism, immune response and many others. C/
EBPβ binding site spans between -190 bp to -177 bp on
SMP30 promoter. This spatial arrangement of C/EBPβ
and Sp1 is critical as Sp1 is known to recruit C/EBPβ to
cryptic C/EBP site [11]. Presence of these two sites in the
minimal promoter region represented as Luc-5 did not
show any significant change in luciferase activity as com-
pared to the Luc-6, but mutation of both Sp1 and C/EBPβ
significantly enhanced the reporter gene activity to about
23%. Thus, it is reasonable to believe that direct or indi-
rect interaction between Sp1 and C/EBPβ in presence of
some other regulatory factor occurs at transcriptional level
Electrophoretic mobility shift assay to confirm the binding of  Aml-1a transcription factor to DNase I protected site FP 6:  Lane 1, labeled FP 6 oligonucleotide duplex with 6 μg RLNE;  Lane 2–8, describe the competition with 100 fold molar  excess of unlabeled homologous self, GATA consensus,  GATA1 consensus, GATA2 consensus, GATA3 consensus,  Aml-1a and nonspecific Lyf-1 oligonucleotide duplex respec- tively Figure 6
Electrophoretic mobility shift assay to confirm the 
binding of Aml-1a transcription factor to DNase I 
protected site FP 6: Lane 1, labeled FP 6 oligonucle-
otide duplex with 6 μg RLNE; Lane 2–8, describe the 
competition with 100 fold molar excess of unlabeled 
homologous self, GATA consensus, GATA1 consen-
sus, GATA2 consensus, GATA3 consensus, Aml-1a 
and nonspecific Lyf-1 oligonucleotide duplex respec-
tively. Electrophoretic mobility shift assay to confirm the binding of  GATA1 transcription factor to DNase I protected site FP 5:  Lane 1, labeled FP 5 oligonucleotide duplex with 6 μg RLNE;  Lane 2–4, describe the competition with 100 fold molar  excess of unlabeled homologous self, GATA1 consensus and  Lyf-1 consensus Figure 5
Electrophoretic mobility shift assay to confirm the 
binding of GATA1 transcription factor to DNase I 
protected site FP 5: Lane 1, labeled FP 5 oligonucle-
otide duplex with 6 μg RLNE; Lane 2–4, describe the 
competition with 100 fold molar excess of unlabeled 
homologous self, GATA1 consensus and Lyf-1 con-
sensus.BMC Molecular Biology 2008, 9:43 http://www.biomedcentral.com/1471-2199/9/43
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in SMP30 promoter which causes a repression in SMP30
promoter activity. Transient transfection of 5' -deletion
fragments revealed the presence of a repressor element
between -513 to -352 bp, as deletion of this region caused
41% decrease in reporter activity. Our DNase I footprint-
ing study showed three putative transcription factor bind-
ing sites within this region (Figure 12). In order to
confirm the potential repressor among these DNase I pro-
tected sites, we carried out site directed mutagenesis stud-
ies of these three sites and subsequent transfection along
with wild type (Luc-3). This result suggested a significant
enhancement of reporter activity of Luc 3–3 mutated frag-
ment by ~59%, Luc3-2 by 27% and Luc 3–1 by 29%. (Fig-
ure 13). TFSEARCH indicated the binding of SRY to wild
type site Luc 3–3, GATA-2 to Luc 3–2 and CdxA to Luc 3–
1 sequences, which is confirmed by competitive EMSA.
Earlier reports depicted the tissue specific expression of
SRY in testes [12] where it involve in testes determination
and differentiation in mammals. Though expression of
SRY in substantia nigra of adult male rodents in tyrosin
hydroxylase expressing neurons has also been reported
but its expression in liver and kidney is still obscure [13].
So the identified transcription factors might be SRY like
proteins which bind to a similar binding site as SRY. The
affinity of SRY for double-stranded DNA varies with DNA
sequence and shares a conserved DNA binding domain
(HMG-box) NACAAT [14]. SRY is reported to bind and
negatively regulates the androgen receptor gene promoter
[15]. We also suggest that GATA-2 and CdxA might be
interacting directly or indirectly with SRY to bring about
repression of SMP30 gene.
Conclusion
Transcription factors Sp1, C/EBPβ, SRY, GATA-2 and
CdxA, binding within -513 of SMP30 promoter, have sig-
nificant role in regulation of SMP30 gene expression.
Electrophoretic mobility shift assay of DNase I protected site  FP 10: Lane 1, labeled FP 10 oligonucleotide duplex with 6 μg  RLNE; Lane 2–3, describe the competition with 100 fold  molar excess of unlabeled homologous self, and non specific  C/EBP consensus Figure 8
Electrophoretic mobility shift assay of DNase I pro-
tected site FP 10: Lane 1, labeled FP 10 oligonucle-
otide duplex with 6 μg RLNE; Lane 2–3, describe the 
competition with 100 fold molar excess of unlabeled 
homologous self, and non specific C/EBP consensus. 
Binding of no transcription factor was observed in 
TFSEARCH data base to this site.
Electrophoretic mobility shift assay to confirm the binding of  GATA1 transcription factor to DNase I protected site FP 8:  Lane 1, labeled FP 8 oligonucleotide duplex with 6 μg RLNE;  Lane 2–4, describe the competition with 100 fold molar  excess of unlabeled homologous self, GATA1 consensus, and  Lyf-1 consensus Figure 7
Electrophoretic mobility shift assay to confirm the 
binding of GATA1 transcription factor to DNase I 
protected site FP 8: Lane 1, labeled FP 8 oligonucle-
otide duplex with 6 μg RLNE; Lane 2–4, describe the 
competition with 100 fold molar excess of unlabeled 
homologous self, GATA1 consensus, and Lyf-1 con-
sensus.BMC Molecular Biology 2008, 9:43 http://www.biomedcentral.com/1471-2199/9/43
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Methods
Preparation of nuclear extract
Nuclear extract from liver of adult (5 months) male rats
(Fisher 344) were prepared as described previously [16].
Briefly, liver slices were homogenized in 4 volumes (w/v)
of ice-cold buffer containing 0.25 M sucrose, 15 mM Tris-
HCl (pH 7.9), 16 mM KCl, 15 mM NaCl, 5 mM EDTA, 1
mM EGTA, 1 mM DTT, 0.15 mM spermine, and 0.15 mM
spermidine; supplemented with the following protease
inhibitors: 0.1 mM PMSF, 2 μg/ml leupeptin, 5 μg/ml
aprotonin. After centrifugation for 10 minutes at 2000 ×
g, the pellets were resuspended in 4 volumes of ice-cold
buffer (10 mM HEPES; pH 7.9, 1.5 mM MgCl2, 10 mM
KCl, and protease inhibitors). The nuclei were pelleted
down by centrifugation for 10 minutes at 4000 × g, and
resuspended in ice cold buffer of 10 mM HEPES (pH 7.9),
0.75 mM MgCl2, 0.5 M KCl, 0.5 mM EDTA, 12.5% glycerol
and protease inhibitors. After incubation on ice for 30
minutes with continuous agitation, the supernatants con-
taining the nuclear extracts were collected by centrifuga-
tion for 30 minutes at 14,000 × g, frozen in liquid
nitrogen and stored in -70°C until used. All manipula-
tions were carried out at 4°C. Protein concentrations were
determined by the Bradford protein assay reagent (Sigma,
USA).
DNase I footprinting
DNase I footprinting was carried out as described before
[7]. Briefly, end-labeled DNA fragments (50 fmoles) were
incubated with 50 μg of rat liver nuclear extract and 2 μg
of poly (dI-dC) in binding buffer containing 10 mM Tris-
HCl (pH 7.5), 50 mM NaCl, 1 mM EDTA, 1 mM DTT, 5%
Electrophoretic mobility shift assay to confirm the binding of  SRY to DNase I protected site FP 11: Lane 1, labeled FP 11  oligonucleotide duplex with 6 μg RLNE; Lane 2–4, describe  the competition with 100 fold molar excess of unlabeled  homologous self, SRY and non specific C/EBP consensus Figure 9
Electrophoretic mobility shift assay to confirm the 
binding of SRY to DNase I protected site FP 11: Lane 
1, labeled FP 11 oligonucleotide duplex with 6 μg 
RLNE; Lane 2–4, describe the competition with 100 
fold molar excess of unlabeled homologous self, SRY 
and non specific C/EBP consensus.
Relative luciferase activity of different 5' -serially deleted SMP30 promoter-reporter constructs were transfected in RAG cells Figure 10
Relative luciferase activity of different 5' -serially deleted SMP30 promoter-reporter constructs were trans-
fected in RAG cells. The results were obtained after normalization with ß-galactosidase activity. All transfections were 
repeated in duplicates and the results are expressed as the mean of five different experiments ± S.D. On left, a schematic rep-
resentation of all the 5' -deleted luciferase constructs used for transfection is depicted. Approximate locations of transcription 
factor binding sites are shown.BMC Molecular Biology 2008, 9:43 http://www.biomedcentral.com/1471-2199/9/43
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glycerol at room temperature for 30 minutes. Subsequent
to binding reaction 7.5 mM MgCl2 and 5 mM CaCl2 were
added and samples were incubated at room temperature
with DNase I (0.25 U, Roche, USA) for 60 s. Ten to twenty
folds less DNase I was used for control experiments with-
out nuclear extracts. DNase I enzyme digestion was
stopped by the addition of an equal volume of 1% SDS,
20 mM EDTA, 400 mM NaCl, 100 μg/ml yeast tRNA and
200 μg/ml proteinase K. Following incubation at 45°C for
60 minutes, samples were extracted twice with phenol/
chloroform, precipitated with ethanol and electro-
phoresed on 6% polyacrylamide sequencing gel. After
electrophoresis, gels were dried on Whatman filter paper
and autoradiographed. Primers used for generating end
labeled DNA fragments for footprinting of the region -
513/-352 bp are: 5' -GCCTCATGCAAGGAAGCAAG-3' SS
and 5' -GATAATGGCAGGTATGAGGG-3' AS. Primers
used for footprinting from -2750 bp to -777 bp are shown
in table 1.
Electrophoretic mobility shift assay (EMSA)
Oligonucleotides (both strands) corresponding to identi-
fied DNase I protected sites (table 2, 3, 5 and 6) were syn-
thesized. For each site, one strand was end-labeled with [γ-
32P] ATP using T4 polynucleotide kinase and annealed to
its complementary unlabeled strand. Nuclear extracts (4–
6 μg) were incubated with 20 fmoles of radiolabeled oli-
gonucleotide duplex in 30 μl reaction containing 10 mM
Tris-HCl (pH 7.5), 50 mM NaCl, 1 mM EDTA, 1 mM DTT,
5 % glycerol and 1.0 μg poly (dI-dC) for 20 minutes at
room temperature. In competition experiments, 100-fold
molar excess of unlabeled oligonucleotide duplexes were
added during preincubation period. For antibody shift
assay, C/EBPβ antibody (Santacruz, USA) was added after
addition of nuclear extract and incubated at 4°C for 10
min. Free DNA and protein bound DNA was separated on
5% non-denaturing polyacrylamide gel in 0.5 X Tris-boric
acid-EDTA (TBE). After electrophoresis, gels were blotted
onto filter paper, dried and autoradiographed.
Construction of 5' and 3' -serially deleted SMP30 
fragments and it's cloning into pGL3-Basic vector
To construct 5' -serially deleted SMP30 fragments Luc-
SMP-XhoI reverse primer and the forward primers as men-
tioned in table 4, containing Kpn1 sites were used. The
PCR amplification was carried out using step cycles (94°C
for 30 s, 62°C for 30 s, 72°C for 30 s) for 35 cycles with a
final extension at 72°C for 10 minutes. Then the PCR
products were purified using QIAquick Gel Extraction Kit
(Qiagen, USA). The serially deleted fragments and pGL3-
Basic vector were digested with KpnI and XhoI enzyme
(MBI Fermentas). The digested 5' -serially deleted frag-
ments were then ligated into restriction enzyme digested
pGL3-Basic vector using DNA ligase (USB, USA). The
cloned fragments were then confirmed by vector specific
PCR using RV and GL2 primer, and also by sequencing.
Site-directed mutagenesis
Five to six bases of the transcription factor core binding
site were mutated as shown in the table 5 (bases in small
letter represents mutated base). For mutagenesis of tran-
scription factors two sets of PCR were carried out using the
following combination of primers: For Sp1: MutSp1
sense/Luc-SMP-XhoI antisense and Luc 5 sense/Mut Sp1
antisense; for C/EBP: Mut C/EBP sense/Luc-SMP-XhoI
antisense and Luc 5 sense/Mut C/EBP antisense; for Mut
Luc 3–1: Mut Luc3-1 sense/Luc-SMP-XhoI antisense and
Luc-SMP-3 sense/Mut Luc 3–1 antisense; for Mut Luc 3–2:
Mut Luc 3–2 sense/Luc-SMP-XhoI antisense and Luc-3
sense/Mut Luc 3–2 antisense; for Mut Luc 3–3: Mut Luc 3–
Luciferase analysis of 3' -deleted Luc 6 constructs as compared to wild type Luc 6 construct showing ~ 28% reduction of  reporter activity Figure 11
Luciferase analysis of 3' -deleted Luc 6 constructs as compared to wild type Luc 6 construct showing ~ 28% 
reduction of reporter activity. All transfections were repeated in duplicates and the results are expressed as the mean of 
two different experiments ± S.D. On right, a schematic representation of 3' deleted luciferase construct used for transfection 
is depicted along with wild Luc 6. Approximate locations of transcription factor binding sites are shown.BMC Molecular Biology 2008, 9:43 http://www.biomedcentral.com/1471-2199/9/43
Page 11 of 15
(page number not for citation purposes)
DNase I footprinting pattern of the repressor region (-513 to -352) Figure 12
DNase I footprinting pattern of the repressor region (-513 to -352). Lane1,2 and 9,10 refer to sequencing reaction 
ladder obtained by taking the same labeled primer used in PCR for DNase I footprinting. Lane 3,4,5 represent DNA treated 
with DNase I in absence of nuclear protein. Lane 6,7,8 represent DNA treated with DNase I in presence of 50 μg rat liver 
nuclear extract (RLNE). The DNase I protected sites are marked on right site and the sequences are given in table 3. DNase I 
footprinting was carried out with fragments generated by labeled forward primer.BMC Molecular Biology 2008, 9:43 http://www.biomedcentral.com/1471-2199/9/43
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DNase I protected sites, Luc 3–1, Luc 3–2 and Luc 3–3 were mutated at their core binding sites Figure 13
DNase I protected sites, Luc 3–1, Luc 3–2 and Luc 3–3 were mutated at their core binding sites. Reporter activity 
of the three mutated construct along with wild type Luc 3 construct is represented on the right site and the schematic repre-
sentation of the mutated sites along with wild type Luc 3 on left site. All transfections were repeated in duplicates and the 
results are expressed as the mean of three different experiments ± S.D Approximate location of the transcription factor bind-
ing to wild type Luc 3 and site directed mutated construct are shown. Mutation of site 3 shows a significant (~59%) increase in 
luciferase activity as compared to wild type Luc3.
Electrophoretic mobility shift assay (EMSA) for site Luc 3–3  to confirm the binding of SRY transcription factor Figure 14
Electrophoretic mobility shift assay (EMSA) for site 
Luc 3–3 to confirm the binding of SRY transcription 
factor.Lane 1, labeled oligonucleotide duplex with 6 μg 
RLNE; Lane 2–5, 100 fold molar excess of unlabeled homolo-
gous self, SRY consensus, mutated Luc 3–3, nonspecific oligo-
nucleotide duplex (NFkB). Lane 6, labeled Mut 3–3 
oligonucleotide duplex with 6 μg RLNE.
EMSA for site Luc 3–2 to confirm the binding of GATA-2  transcription factor Figure 15
EMSA for site Luc 3–2 to confirm the binding of 
GATA-2 transcription factor.Lane 1, labeled mutated oli-
gonucleotide duplex with 6 μg RLNE; Lane 2, labeled oligonu-
cleotide duplex with 6 μg RLNE; lane3 -5, 100 fold molar 
excess of unlabeled homologous self, GATA-2 consensus, 
and nonspecific (NFkB) oligonucleotide duplex (NFkB).BMC Molecular Biology 2008, 9:43 http://www.biomedcentral.com/1471-2199/9/43
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3 sense/Luc-SMP-XhoI antisense and Luc-SMP-3 sense/
Mut Luc 3–3 antisense. The PCR amplification was per-
formed using step cycles (94°C for 1 min, 62°C for 30 s,
72°C 30 s) for 35 cycles with a final extension at 72°C for
10 minutes. Both the PCR products were purified using
QIAquick Gel Extraction Kit. DNA was eluted using 30 μl
of autoclaved deionised water. 5 μl of each PCR product
was used as a template for the second round of PCR. For
example: for construction of mutant Sp1 site: 5μl each of
the PCR product Mut Sp1 sense/Luc-SMP-XhoI antisense
and Luc-5 sense/Mut Sp1 antisense was used as template.
For construction of mutant Sp1 and mutant C/EBP, Luc-5
and Luc-SMP-XhoI was used as forward and reverse prim-
ers. For construction of mutant Luc 3–1, Luc 3–2 and Luc
3–3, Luc-3 and Luc-SMP-XhoI was used as forward and
reverse primers. PCR amplification was carried out using
the same parameters as mentioned above. Then the PCR
products were purified using QIAquick Gel Extraction Kit.
The fragments with mutated transcription factor binding
sites, having KpnI and XhoI restriction sites and pGL3-
Basic vector were digested with KpnI and XhoI enzyme.
The fragments were then ligated into restriction enzyme
digested pGL3-Basic vector using DNA ligase. The cloned
fragments were then confirmed by vector specific PCR
using RV and GL2 primer, and the mutation was con-
firmed by sequencing.
Transient transfection and luciferase assay
Transient transfections were carried out using RAG cells
(mouse renal adenocarcinoma cell line) as SMP30 is also
expressed in kidney. The cells were plated at a density of 2
× 105 cells per well in six well plates, 18 h before transfec-
tion. For transient transfection 2 μg of respective reporter
plasmid DNA and 0.5 μg of pSV-β-gal control vector
Reporter activity of site direct mutated Sp1, site direct mutated C/EBP and site direct mutated Sp1 and C/EBP sites reporter  constructs along with wild type Luc 5 on right site and the schematic representation of the mutated Sp1 and C/EBP sites along  with wild type Luc 5 sites on left site Figure 16
Reporter activity of site direct mutated Sp1, site direct mutated C/EBP and site direct mutated Sp1 and C/EBP sites reporter 
constructs along with wild type Luc 5 on right site and the schematic representation of the mutated Sp1 and C/EBP sites along 
with wild type Luc 5 sites on left site. All transfections were repeated in duplicates and the results are expressed as the mean of three differ-
ent experiments ± S.D Approximate location of the transcription factor binding to wild type Luc 5 and site directed mutated construct are 
shown. A significant decrease (~16%) in reporter activity of mutated Sp1 construct is seen as compared with wild type Luc 5. There is no signifi-
cant change in reporter activity with mutated C/EBP construct. Double mutation of Sp1 and C/EBP enhance the reporter activity by 23% as com-
pared to wild type Luc 5.
Electrophoretic mobility shift assay to confirm the binding of  Sp1 transcription factor Figure 17
Electrophoretic mobility shift assay to confirm the 
binding of Sp1 transcription factor.Lane 1, labeled 
mutated SMP-Sp1 oligonucleotide duplex with 6 μg RLNE; 
Lane 2–6, labeled SMP-Sp1 oligonucleotide duplex with 6 μg 
RLNE; Lane 3–6, describe the competition with 100 fold 
molar excess of unlabeled homologous self, Sp1 consensus, 
Mut SMP-Sp1 and nonspecific SRY oligonucleotide duplex 
respectively.BMC Molecular Biology 2008, 9:43 http://www.biomedcentral.com/1471-2199/9/43
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(Promega, USA) or 100 ng of pRL-TK control vector were
cotransfected into cells using FuGENE reagent (Roche,
USA). After 24 h post transfection, the cells were har-
vested, lysed, centrifuged and the lysate was used for luci-
ferase assay using the luciferase assay system (Promega,
USA). The colorimetric β-galactosidase assay was per-
formed using β-Gal assay kit (Invitrogen, USA) and luci-
ferase activity was divided by the β-galactosidase activity
to normalize for transfection efficiency. For transfection
of mutated constructs Renella was used as an internal con-
trol and dual luciferase assay was preformed to measure
the luciferase reading as per manufacturer's instruction
Table 5: Primers and oligonucleotide used for site- directed mutagenesis.
Mut Luc-3-1 GCTGgAGGCcTAGCTCTGTAGCAGAgTACAccCAAG
Mut Luc-3-2 CAgGGTCCTcGTTCcATtCCaG
Mut Luc-3-3 CCAGTgCAgACgAGCAAGCggCTGTATATgC
SP1-SMP GCTCCCCCCCCCCGCCCCCCCCCAGGG
Mut-SP1 GCTCCtCCtCCtCGtCtCCCtCCAG
C/EBP-SMP ACTGATGTACACATTCCTAAAACTGGC
Mut-C/EBP ACTGgTGgACACAggCCTAggACTGGC
Electrophoretic mobility shift assay to confirm the binding of C/EBP transcription factor Figure 18
Electrophoretic mobility shift assay to confirm the binding of C/EBP transcription factor.Lane 1–5, labeled 
mutated C/EBP oligonucleotide duplex with 6 μg RLNE; Lane 2, C/EBPβ antibody; Lane 3–5, describe the competition with 100 
fold molar excess of unlabeled homologous self, SMP-C/EBP and C/EBP consensus. Lane 6–11, labeled SMP-C/EBP oligonucle-
otide duplex with 6 μg RLNE; Lane 7, C/EBPβ antibody; Lane 8–11, describe the competition with 100 fold molar excess of 
unlabeled homologous self, C/EBP consensus, Mut SMP-C/EBP and nonspecific SRY oligonucleotide duplex respectively. Anti-
body shift is seen with SMP-C/EBP only and not with mutated SMP-C/EBP.Publish with BioMed Central    and   every 
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(Promega, USA). All the transfections were repeated in
duplicates in three to five independent experiments. The
number of independent experiments is being mentioned
in respective figure legends.
Abbreviations
SMP30: Senescence Marker Protein 30; EMSA: Electro-
phoretic Mobility Shift Assay; RLNE: Rat Liver Nuclear
Extract.
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